Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality

Vaccine

Volumn 33, Issue 32, 2015, Pages 4013-4018

  Swanson, Elizabeth C ^a   Gillis, Pete ^a   Hernandez Alvarado, Nelmary ^a   Fernández Alarcón, Claudia ^a   Schmit, Megan ^a   Zabeli, Jason C ^a   Wussow, Felix ^b   Diamond, Don J ^b   Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CMV immune modulation; CMV pp65; CMV vaccine; Congenital CMV infection; Cytomegalovirus (CMV); Glycoprotein B; Guinea pig cytomegalovirus; Pentameric complex

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B; GP83 VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; GLYCOPROTEIN B, SIMPLEXVIRUS; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONGENITAL INFECTION; CONGENITAL VIRAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG MODEL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RATE; MATERNAL CARE; MORTALITY; NONHUMAN; PORCINE MODEL; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; VIRUS LOAD; ANIMAL; BLOOD; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODEL; GUINEA PIG; IMMUNOLOGY; PREVENTION AND CONTROL; ROSEOLOVIRUS; SERODIAGNOSIS; SURVIVAL ANALYSIS; TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIGS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEUTRALIZATION TESTS; PHOSPHOPROTEINS; PREGNANCY; ROSEOLOVIRUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84937517235     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.019     Document Type: Article

References (50)

1. Griffiths P., Baraniak I., Reeves M. The pathogenesis of human cytomegalovirus. J Pathol 2015, 235:288-297.
2. Schleiss M.R. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets 2011, 11:449-465.
3. Boeckh M., Geballe A.P. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011, 121:1673-1680.
4. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004, 39:233-239.
5. Griffiths P., Plotkin S., Mocarski E., Pass R., Schleiss M., et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013, 31(Suppl 2):B197-B203.
6. Krause P.R., Bialek S.R., Boppana S.B., Griffiths P.D., Laughlin C.A., Ljungman P., et al. Priorities for CMV vaccine development. Vaccine 2013, 32:4-10.
7. Schleiss M.R. Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin Dev Immunol 2013, 2013:501801.
8. Sung H., Schleiss M.R. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010, 9:1303-1314.
9. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
10. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
11. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
12. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., Langston A.A., Chu A.H., Wloch M.K., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
13. Schleiss M.R. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next. Future Virol 2013, 8:1161-1182.
14. Dogra P., Sparer T.E. What we have learned from animal models of HCMV. Methods Mol Biol 2014, 1119:267-288.
15. Hashimoto K., Yamada S., Katano H., Fukuchi S., Sato Y., Kato M., et al. Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta. Vaccine 2013, 31:3199-3205.
16. Crumpler M.M., Choi K.Y., McVoy M.A., Schleiss M.R. A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine 2009, 27:4209-4218.
17. Choi Y.C., Hsiung G.D. Cytomegalovirus infection in guinea pigs. II. Transplacental and horizontal transmission. J Infect Dis 1978, 138:197-202.
18. Schleiss M.R., Bourne N., Jensen N.J., Bravo F., Bernstein D.I. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. Viral Immunol 2000, 13:155-167.
19. Olejniczak M.J., Choi K.Y., McVoy M.A., Cui X., Schleiss M.R. Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model. Virol J 2011, 8:89.
20. Cranage M.P., Kouzarides T., Bankier A.T., Satchwell S., Weston K., Tomlinson P., et al. Identification of the human cytomegalovirus glycoprotein-b gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 1986, 5:3057-3063.
21. Britt W.J., Harrison C. Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus. Virology 1994, 201:294-302.
22. Schleiss M.R. Cloning and characterization of the guinea pig cytomegalovirus glycoprotein B gene. Virology 1994, 202:173-185.
23. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996, 70:7569-7579.
24. Gillis P.A., Hernandez-Alvarado N., Gnanandarajah J.S., Wussow F., Diamond D.J., Schleiss M.R. Development of a novel, guinea pig-specific IFN-gamma ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 2014, 32:3963-3970.
25. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007, 195:789-798.
26. Schleiss M.R., Bourne N., Bernstein D.I. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003, 188:1868-1874.
27. Schleiss M.R., Bourne N., Stroup G., Bravo F.J., Jensen N.J., Bernstein D.I. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004, 189:1374-1381.
28. Yue Y., Kaur A., Eberhardt M.K., Kassis N., Zhou S.S., Tarantal A.F., et al. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 2007, 81:1095-1109.
29. Yue Y., Wang Z., Abel K., Li J., Strelow L., Mandarino A., et al. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol (Berl) 2008, 197:117-123.
30. Morello C.S., Ye M., Hung S., Kelley L.A., Spector D.H. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 2005, 79:159-175.
31. Bratcher D.F., Bourne N., Bravo F.J., Schleiss M.R., Slaoui M., Myers M.G., et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995, 172:944-950.
32. Leviton M.P., Lacayo J.C., Choi K.Y., Hernandez-Alvarado N., Wey A., Schleiss M.R. An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model. Clin Dev Immunol 2013, 2013:906948.
33. Gnanandarajah J.S., Gillis P.A., Hernandez-Alvarado N., Higgins L., Markowski T.W., Sung H., et al. Identification by mass spectrometry and immune response analysis of guinea pig cytomegalovirus (GPCMV) pentameric complex proteins GP129, 131 and 133. Viruses 2014, 6:727-751.
34. Yamada S., Nozawa N., Katano H., Fukui Y., Tsuda M., Tsutsui Y., et al. Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 2009, 391:99-106.
35. Auerbach M., Yan D., Fouts A., Xu M., Estevez A., Austin C.D., et al. Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread. Virology 2013, 441:75-84.
36. Schleiss M.R., Choi K.Y., Anderson J., Mash J.G., Wettendorff M., Mossman S., et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine 2014, 32:2756-2762.
37. Wang Z., La Rosa C., Li Z., Ly H., Krishnan A., Martinez J., et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 2007, 25:1132-1141.
38. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004, 104:847-856.
39. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 2004, 78:3965-3976.
40. Schleiss M.R. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J 2006, 47:65-72.
41. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89:10847-10851.
42. Abel K., Martinez J., Yue Y., Lacey S.F., Wang Z., Strelow L., et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 2011, 85:2878-2890.
43. Browne E.P., Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA 2003, 100:11439-11444.
44. Abate D.A., Watanabe S., Mocarski E.S. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol 2004, 78:10995-11006.
45. Hartikka J., Bozoukova V., Morrow J., Rusalov D., Shlapobersky M., Wei Q., et al. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother 2012, 8:1595-1606.
46. Malouli D., Hansen S.G., Nakayasu E.S., Marshall E.E., Hughes C.M., Ventura A.B., et al. Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest 2014, 124:1928-1944.
47. Kreijtz J.H., Goeijenbier M., Moesker F.M., van den Dries L., Goeijenbier S., De Gruyter H.L., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014, 14:1196-1207.
48. Wussow F., Yue Y., Martinez J., Deere J.D., Longmate J., Herrmann A., et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 2013, 87:1322-1332.
49. Wussow F., Chiuppesi F., Martinez J., Campo J., Johnson E., Flechsig C., et al. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 2014, 10:e1004524.
50. Kabanova A., Perez L., Lilleri D., Marcandalli J., Agatic G., Becattini S., et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci USA 2014, 111:17965-17970.